Evidence map›Paper›PMID 36063223›Full record

ReviewArchives of microbiology2022

Anti-lung cancer properties of cyanobacterial bioactive compounds.

Mirza S Baig, Sajjan Rajpoot, Tomokazu Ohishi, Rajkumar Savai, Sascha Seidel, Nina A Kamennaya, Evgeny E Bezsonov, Alexander N Orekhov, Pratik Mahajan, Kundan Solanki and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mirza S Baig *Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, 453552, Indore, India. msb.iit@iiti.ac.in.ORCID http://orcid.org/0000-0001-8292-7130
Sajjan Rajpoot *Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, 453552, Indore, India.
Tomokazu Ohishi *Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Numazu-shi, Shizuoka, Japan.
Rajkumar SavaiInstitute for Lung Health (ILH), Justus Liebig University, Giessen, Germany.
Sascha SeidelInstitute for Lung Health (ILH), Justus Liebig University, Giessen, Germany.
Nina A KamennayaFrench Associates Institute for Agriculture and Biotechnology of Drylands, Blaustein Institutes for Desert Research, Ben-Gurion University of the Negev, Sede Boqer Campus, Midreshet Ben Gurion, Israel.
Evgeny E BezsonovLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 8 Baltiiskaya Street, 125315, Moscow, Russia.
Alexander N OrekhovLaboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 8 Baltiiskaya Street, 125315, Moscow, Russia.
Pratik MahajanDepartment of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, 453552, Indore, India.
Kundan SolankiDepartment of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, 453552, Indore, India.
Uzma SaqibDepartment of Chemistry, Indian Institute of Technology Indore (IITI), Indore, Madhya Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer, the most prevalent gender-independent tumor entity in both men and women, is among the leading cause of cancer-related deaths worldwide. Despite decades of effort in developing improved therapeutic strategies including immunotherapies and novel chemotherapeutic agents, only modest improvements in outcome and long-term survival of lung cancer patients have been achieved. Therefore, exploring new and exceptional sources for bioactive compounds that might serve as anti-cancer agents might be the key to improving lung cancer therapy. On account of diverse forms, cyanobacteria might serve as a potential source for compounds with potential therapeutic applicability against malignant disorders, including cancer. The assorted arrays of metabolic mechanisms synthesize a plethora of bioactive compounds with immense biological potential. These compounds have been proven to be effective against various cancer cell lines and xenograft animal models. The present review provides an overview of the most promising cyanobacteria-derived bioactive compounds proven to exhibit anti-cancer properties in in-vitro and in-vivo studies and highlights their applicability as potential therapeutic agents with a focus on their anti-lung cancer properties.

Indexed as

Antineoplastic AgentsCyanobacteriaNeoplasmsAnimalsFemaleHumansAntineoplastic AgentsBioactive compoundsCancer signalingCyanobacteriaLung cancerTherapeutic candidates

Identifiers

PMID36063223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.